SAN DIEGO — Visual field defect on baseline 10-2 testing most effectively predicted subsequent progression on 24-2 testing in patients with glaucoma, Michael J. Sullivan-Mee, OD, FAAO, said at an ...

Please provide your email address to receive an email when new articles are posted on . At 2 years, 74% of Black patients and 66.4% of white patients who received ranibizumab achieved vision of 20/40 ...

PARIS--(BUSINESS WIRE)--Regulatory News: ... direct injection of lenadogene nolparvovec may be more effective than the contralateral therapeutic effect ... The paper, published in the July 2025 issue ...

Density loss in the optic nerve head capillary could lead to a faster rate of visual field progression as well as an increased risk of developing event progression. Glaucoma is best managed through ...

SIGLEC Phase 2b data support AVD-104 as a potential therapy to reduce GA lesion growth, preserve and improve visual acuity, and reduce conversion to neovascular AMD across all GA lesion types at 1 ...